Bringing less harmful and more effective therapies to cancer patients. A monoclonal antibody therapy shown in preclinical tests as 98.9% effective in cancers.
Savoy Pharmaceuticals is an emerging therapeutic company in the field of Immunotherapy. Savoy's first target is their patented novel tumor marker found on the surface of several cancer types s well as viruses. The company is preparing the IND application for Phase I clinical trials for liver and pancreatic cancers. Comprised of a team of Dr.'s and MBA's with backgrounds from UCLA, University of Rochester, BYU, MD Anderson, Roche, and Genentech.